UH15-38 TFA is a potent RIPK3 inhibitor with an IC50 value of 20 nM. UH15-38 TFA blocks IAV (influenza A virus)-activated necroptosis. UH15-38 TFA dampens IAV-induced lung injury [1].
In Vivo, UH15-38 (30 mg/kg; i.p.; daily for 4 days) TFA inhibits IAV (Influenza A virus)-induced lung injury in mice[1].
In Vitro, UH15-38 (0-1000 nM; 12 h) TFA decreases the expression of pMLKL induced by TCZ in a dose-dependent manner[1]. UH15-38 (0-1000 nM) TFA protects type I alveolar epithelial cells from canonical TNF-induced necroptosis and prevents IAV-induced necroptosis[1].
References:
[1]. Gautam A, et al. Necroptosis blockade prevents lung injury in severe influenza. Nature. 2024 Apr;628(8009):835-843.
In Vivo, UH15-38 (30 mg/kg; i.p.; daily for 4 days) TFA inhibits IAV (Influenza A virus)-induced lung injury in mice[1].
In Vitro, UH15-38 (0-1000 nM; 12 h) TFA decreases the expression of pMLKL induced by TCZ in a dose-dependent manner[1]. UH15-38 (0-1000 nM) TFA protects type I alveolar epithelial cells from canonical TNF-induced necroptosis and prevents IAV-induced necroptosis[1].
References:
[1]. Gautam A, et al. Necroptosis blockade prevents lung injury in severe influenza. Nature. 2024 Apr;628(8009):835-843.
















